Wayne L. Brinster

TriPath Imaging, Inc. engages in the development, manufacture, and market of equipment and products for cervical cytology screening. The company was founded on November 15, 1996 and is headquartered in Burlington, NC.

Wheaton Industries, Inc. produces and markets laboratory instruments and equipment. The firm is a marketer, manufacturer and re-packager of containers, laboratory ware, instrumentation and associated products and services sold principally to customers in the general laboratory, life sciences, diagnostics, and reagent/chemicals packaging markets. The company was founded in 1971 and is headquartered in Millville, NJ.

Nirvana Sciences, Inc. develops and commercializes near-infrared fluorescence dyes for use in medical diagnostics and optical imaging. The company was founded by Russell D. Thomas, Jonathan S. Lindsey and Preston C. Linn and is headquartered in Raleigh, NC.

Pointe Scientific, Inc. develops, manufactures, and distributes clinical diagnostic products. It offers general chemistry reagents, analyzers/instruments, standards and calibrators, quality control/quality assurance solutions, instrument specific reagent kits, enzyme immunoassay tests, urine chemistry reagents, liquid stable reagents, consumables, short-dated products, and original equipment manufacturer/private label/custom manufacturing solutions. The company was founded in 1981 and is headquartered in Canton, MI.

Part of Horiba Ltd., Medical Laboratory Solutions, Inc. operates as a medical laboratory. The company is based in Canton, MI. The CEO of the company is Wayne L. Brinster.

MedTest DX, Inc. sells chemistry instruments and reagents. The firm's products include chemistry, Directorug of abuse, hematology, assays, and calibrators. The company was founded in 2011 and is headquartered in Canton, MI.

PreciseDx Ltd. is a British AI company that specializes in oncology diagnostics. The company is based in Altrincham, UK. The company leverage the analysis of morphology features from histology slides to provide more precise patient-specific risk information. The company's proprietary morphology feature array™ allows clinical teams to have access to unmatched insights and accurate, actionable intelligence for disease state characterization to determine the best treatment for each patient. PreciseDx creates disease-specific assays that deliver new levels of pathology information and insight on each patient's risk profile and likely outcomes to aid in treatment decision-making. The company was founded in 2019. Wayne L. Brinster has been the CEO of the company since 2021.